Latest
AL amyloidosis therapy reshapes around daratumumab and emerging amyloid-targeted programs
Daratumumab plus bortezomib first-line, isatuximab follow-on programs, and emerging anti-amyloid antibody therapy are restructuring AL amyloidosis management.
Pulmonary embolism management restructures around catheter-directed therapy and risk stratification
DOAC first-line maturity, catheter-directed thrombolysis and mechanical thrombectomy growth, and structured pulmonary embolism response team (PERT) infrastructure are reshaping pulmonary embolism care.
Hypertrophic cardiomyopathy myosin modulator class matures
Mavacamten commercial maturity, aficamten approval and pivotal data, and emerging follow-on cardiac myosin modulator programs are restructuring obstructive HCM management.
Lipid management therapy widens past statins and PCSK9 monoclonals
Inclisiran maturity, bempedoic acid, lepodisiran and emerging oral PCSK9 programs, and ANGPTL3-targeted therapy are restructuring lipid management.
By signal pillar
Market access & reimbursement
1Scientific
18AL amyloidosis therapy reshapes around daratumumab and emerging amyloid-targeted programs
Daratumumab plus bortezomib first-line, isatuximab follow-on programs, and emerging anti-amyloid antibody therapy are restructuring AL amyloidosis management.
Pulmonary embolism management restructures around catheter-directed therapy and risk stratification
DOAC first-line maturity, catheter-directed thrombolysis and mechanical thrombectomy growth, and structured pulmonary embolism response team (PERT) infrastructure are reshaping pulmonary embolism care.
Hypertrophic cardiomyopathy myosin modulator class matures
Mavacamten commercial maturity, aficamten approval and pivotal data, and emerging follow-on cardiac myosin modulator programs are restructuring obstructive HCM management.
Lipid management therapy widens past statins and PCSK9 monoclonals
Inclisiran maturity, bempedoic acid, lepodisiran and emerging oral PCSK9 programs, and ANGPTL3-targeted therapy are restructuring lipid management.
Heart failure with reduced ejection fraction therapy moves beyond four-pillar standard
Vericiguat addition, mechanism-targeted programs, and emerging genetically-defined HFrEF approaches are reshaping the post-four-pillar landscape.
Chronic kidney disease therapy options widen in non-diabetic populations
Finerenone in non-diabetic CKD, SGLT2 expansion past diabetes, and novel mechanism programs are restructuring CKD management beyond the diabetic kidney disease frame.
Type 1 diabetes therapy reshapes around disease modification and automation
Teplizumab disease modification, automated insulin delivery system maturity, and emerging beta-cell replacement programs are restructuring T1D management.
MASH therapy class establishes after resmetirom approval
Resmetirom commercial uptake plus follow-on FGF21 analogues, GLP-1 plus glucagon, and PPAR-pan agonists are establishing a real metabolic-dysfunction-associated steatohepatitis prescribing class.
Apolipoprotein C3-targeted therapy expands lipid management
ApoC3-targeted programs are widening the triglyceride-lowering toolset and entering routine lipid practice.
Continuous glucose monitoring goes mainstream
Continuous glucose monitoring is expanding beyond type 1 diabetes into type 2 management and even non-diabetic wellness use.
Lipoprotein(a) emerges as a treatable target
Late-stage Lp(a)-lowering programs may close one of cardiovascular medicine's longest-standing risk-factor gaps.
APOL1-targeted therapy and the precision-nephrology turn
Targeted therapy for APOL1-mediated kidney disease marks the first precision-nephrology category in routine practice.
Obesity recognised as a metabolic disease
Coverage decisions and treatment guidelines are catching up with the framing of obesity as a chronic, treatable disease.
GLP-1 as a metabolic platform
Single, dual, and triple agonists are extending GLP-1 therapy beyond diabetes into obesity, cardiovascular, renal, and emerging neurodegenerative use.
Quadruple therapy in heart failure
Heart-failure-with-reduced-ejection-fraction care has settled around four-pillar therapy; the question is whether routine practice keeps up.
Lipid management gets a new tier
PCSK9 inhibitors, lp(a)-targeted therapy, and inclisiran are rebuilding the cardiovascular prevention stack.
MASH becomes a real prescribing category
After years of failed programs, metabolic dysfunction-associated steatohepatitis has its first approved therapies.
CKD therapy stack rebuilt
SGLT2 inhibitors, finerenone, and GLP-1 mechanisms are rebuilding the chronic-kidney-disease therapy stack.
Real-world evidence
3ATTR amyloidosis silencer therapy uptake is transforming a previously underdiagnosed condition
Transthyretin amyloid cardiomyopathy (ATTR-CM) was historically underdiagnosed and undertreated. Approved silencer therapies (siRNA, ASO) and TTR stabilisers have moved the field rapidly, and the diagnostic-pathway access remains the rate-limit on commercial uptake.
Hypertension treatment intensification gap remains the underdeveloped commercial opportunity
Real-world hypertension control rates across major markets remain substantially below guideline targets, with the treatment-intensification gap (patients on suboptimal regimens not advanced to combination or specialist therapy) as the principal driver. The commercial opportunity in closing this gap is large and is being addressed by combination-therapy programs and by emerging novel mechanisms.
Finerenone CKD uptake reveals the cardio-renal-metabolic prescribing gap
Real-world finerenone uptake in chronic kidney disease patients with type 2 diabetes has been slower than the pivotal trial benefit profile would predict. The drivers are specialist coordination across cardiology, nephrology and endocrinology, and the operational complexity of integrating finerenone into existing regimens.